{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T16:55:49Z","timestamp":1789232149322,"version":"build-2803163510"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2014,4,7]],"date-time":"2014-04-07T00:00:00Z","timestamp":1396828800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["BMC Psychiatry"],"published-print":{"date-parts":[[2014,12]]},"DOI":"10.1186\/1471-244x-14-103","type":"journal-article","created":{"date-parts":[[2014,4,7]],"date-time":"2014-04-07T20:00:14Z","timestamp":1396900814000},"source":"Crossref","is-referenced-by-count":15,"title":["Study protocol: safety correction of high dose antipsychotic polypharmacy in Japan"],"prefix":"10.1186","volume":"14","author":[{"given":"Tsuruhei","family":"Sukegawa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ataru","family":"Inagaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshio","family":"Yamanouchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiya","family":"Inada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Yoshio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reiji","family":"Yoshimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nakao","family":"Iwata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,4,7]]},"reference":[{"key":"1596_CR1","doi-asserted-by":"publisher","first-page":"674","DOI":"10.4088\/JCP.v69n0422","volume":"69","author":"CU Correll","year":"2008","unstructured":"Correll CU: Antipsychotic polypharmacy, part 1: Shotgun approach or targeted cotreatment. J Clin Psychiatry. 2008, 69: 674-675. 10.4088\/JCP.v69n0422.","journal-title":"J Clin Psychiatry"},{"key":"1596_CR2","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.schres.2012.03.018","volume":"138","author":"JA Gallego","year":"2012","unstructured":"Gallego JA, Bonetti J, Zhang J, Kane JM, Correll CU: Prevalence and correlates of antipsychotic polypharmacy: a systematic review and meta-regression of global and regional trends from the 1970s to 2009. Schizophr Res. 2012, 138: 18-28. 10.1016\/j.schres.2012.03.018.","journal-title":"Schizophr Res"},{"key":"1596_CR3","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1055\/s-2004-827174","volume":"37","author":"K Sim","year":"2004","unstructured":"Sim K, Su A, Leong JY, Yip K, Chong MY, Fujii S, Yang S, Ungvari GS, Si T, Chung EK, Tsang HY, Shinfuku N, Kua EH, Tan CH: High dose antipsychotic use in schizophrenia: findings of the REAP (research on east Asia psychotropic prescriptions) study. Pharmacopsychiatry. 2004, 37: 175-179. 10.1055\/s-2004-827174.","journal-title":"Pharmacopsychiatry"},{"key":"1596_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.schres.2009.05.018","volume":"113","author":"S Weinmann","year":"2009","unstructured":"Weinmann S, Read J, Aderhold V: Influence of antipsychotics on mortality in schizophrenia: systematic review. Schizophr Res. 2009, 113: 1-11. 10.1016\/j.schres.2009.05.018.","journal-title":"Schizophr Res"},{"key":"1596_CR5","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1002\/hup.1272","volume":"27","author":"T Yoshio","year":"2012","unstructured":"Yoshio T, Inada T, Uno J, Miwa T, Kitagawa K, Miyahara Y, Umeda K, Kato T, Inagaki A, Nabeshima T: Prescription profiles for pharmacological treatment of Japanese inpatients with schizophrenia: comparison between 2007 and 2009. Hum Psychopharmacol. 2012, 27: 70-75. 10.1002\/hup.1272.","journal-title":"Hum Psychopharmacol"},{"key":"1596_CR6","first-page":"37","volume-title":"Development of the Treatment and Rehabilitation Guideline for Schizophrenia and the Demonstration Study of its Effectiveness: Final Report of the National Project Team, Supported by the Research Grant for Nervous and Mental Disorders from the Ministry of H","author":"T Sukegawa","year":"2004","unstructured":"Sukegawa T, Sakamto H, Kanazawa K, Inagaki A, Murasugi K, Yoshizumi A, Oshima I, Tsukada K, Urata J: Aproposal of Reduction and Simplification of Polypharmacy of Antipsychotics. Development of the Treatment and Rehabilitation Guideline for Schizophrenia and the Demonstration Study of its Effectiveness: Final Report of the National Project Team, Supported by the Research Grant for Nervous and Mental Disorders from the Ministry of Health, Labour and Welfare, Japan in 2001. Edited by: Urata J. 2004, Japan: The National Project Team, supported by the research grant for nervous andmental disorders from the Ministry of Health, Labour and Welfare, 37-43. in Japanese with English abstract"},{"key":"1596_CR7","first-page":"169","volume":"1","author":"T Sukegawa","year":"2008","unstructured":"Sukegawa T, Ito T, Hasegawa M, Mizuno Y, Inagaki A, Sakamoto H, Kanazawa K, Yoshizumi A, Oshima I, Misawa F, Iwanaga H, Uramura K, Saeki Y, Miyakawa A, Yamauchi Y, Doi K, Hayashi Y, Takata K, Ishizaki K, Amakane H, Morita Y, Hagiwara T, Uchino H, Ashizawa Y, Yabana T, Iwasaki S, Kaigai H, Kishida M, Nagao K, Terai E, et al: A randomized controlled trial on the dose reduction and simplification for polypharmacy of antipsychotics. Tottori J Clin Res. 2008, 1: 169-181. in Japanese with English abstract","journal-title":"Tottori J Clin Res"},{"key":"1596_CR8","first-page":"887","volume":"5","author":"A Inagaki","year":"2008","unstructured":"Inagaki A, Inada T: Dose equivalence of psychotropic drugs. Part XXI: dose equivalence of novel antipsychotics: blonanserin. Jap J Clin Psychopharmacol. 2008, 5: 887-890. (in Japanese)","journal-title":"Jap J Clin Psychopharmacol"},{"key":"1596_CR9","first-page":"231","volume":"77","author":"A Tanabe","year":"2000","unstructured":"Tanabe A: A study reducing the number of antipsychotic drugs in chronic schizophrenia. Keio Igaku. 2000, 77: 231-239. (in Japanese with English abstract)","journal-title":"Keio Igaku"},{"key":"1596_CR10","first-page":"67","volume-title":"Development of the Treatment and Rehabilitation Guideline for Schizophrenia and the Demonstration Study of its Effectiveness: Final Report of the National Project Team, Supported by the Research Grant for Nervous and Mental Disorders from the Ministry of H","author":"K Murasugi","year":"2004","unstructured":"Murasugi K, Hagiwara T, Shouda S: Attempt to Correct Antipsychotic Administration to Monotherapy and Dose Reduction for Chronic Schizophrenia Patients. Development of the Treatment and Rehabilitation Guideline for Schizophrenia and the Demonstration Study of its Effectiveness: Final Report of the National Project Team, Supported by the Research Grant for Nervous and Mental Disorders from the Ministry of Health, Labour and Welfare, Japan in 2001. Edited by: Urata J. 2004, Japan: National Project Team, Supported by the Research Grant for Nervous and Mental Disorders from the Ministry of Health, Labour and Welfare, 67-73. in Japanese"},{"key":"1596_CR11","first-page":"511","volume":"14","author":"T Sukegawa","year":"2011","unstructured":"Sukegawa T: The table indicating the reduction speed of antipsychotics for reduction and simplification of drug prescriptions. Jap J Clin Psychopharmacol. 2011, 14: 511-515. (in Japanese with English abstract)","journal-title":"Jap J Clin Psychopharmacol"},{"key":"1596_CR12","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1176\/ajp.137.8.992-a","volume":"137","author":"G Chouinard","year":"1980","unstructured":"Chouinard G, Jones BD: Neuroleptic induced supersensitivity psychosis: clinical and pharmacologic characteristics. Am J Psychiatry. 1980, 137: 16-21.","journal-title":"Am J Psychiatry"},{"key":"1596_CR13","volume-title":"Diagnostic and Statistical Manual of Mental Disorder, 4th edn.Text Version (DSM-IV-TR)","author":"American Psychiatric Association","year":"2000","unstructured":"American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorder, 4th edn.Text Version (DSM-IV-TR). 2000, Washington, DC: American Psychiatric Association"},{"key":"1596_CR14","first-page":"389","volume":"36","author":"Y Takekawa","year":"1994","unstructured":"Takekawa Y, Hori A, Tsunashima K, Ishihara I, Uno M, Murakami K, Nishimura Y, Ino K, Hirai T, Kajimura N, Takayama Y, Hayakawa T: Reliability and validity of Japanese version of Manchester Scale. Seishinigaku. 1994, 36: 389-394. in Japanese","journal-title":"Seishinigaku"},{"key":"1596_CR15","volume-title":"A second-generation rating scale for antipsychotic-induced extrapyramidal symptoms: Drug-induced Extrapyramidal Symptoms Scale","author":"T Inada","year":"2009","unstructured":"Inada T, DIEPSS: A second-generation rating scale for antipsychotic-induced extrapyramidal symptoms: Drug-induced Extrapyramidal Symptoms Scale. 2009, Tokyo: Seiwa Shoten Publishers, Inc, in Japanese"},{"issue":"(suppl334","key":"1596_CR16","first-page":"11\u2013","volume":"76","author":"O Lingjaerede","year":"1987","unstructured":"Lingjaerede O, Ahlfors UG, Bech P, Dencker SJ, Elgen K: The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross sectional study of side effects in neuroleptic-treated patients. Acta Psychiatr Scand. 1987, 76 ((suppl334): 11\u2013-100.","journal-title":"Acta Psychiatr Scand"},{"key":"1596_CR17","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1002\/hec.673","volume":"11","author":"A Tsuchiya","year":"2002","unstructured":"Tsuchiya A, Ikeda S, Ikegami N, Nishimura S, Sakai I, Fukuda T, Hamashima C, Hisashige A, Tamura M: Estimating an EQ-5D population value set: the case of Japan. Health Econ. 2002, 11: 341-353. 10.1002\/hec.673.","journal-title":"Health Econ"},{"key":"1596_CR18","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1111\/j.1440-1819.2007.01725.x","volume":"61","author":"Y Kaneda","year":"2007","unstructured":"Kaneda Y, Sumiyoshi T, Keefe R, Ishimoto Y, Numata S, Ohmori T: Brief assessment of cognition in schizophrenia, validation of the Japanese version. Psychiatry Clin Neurosci. 2007, 61: 602-609. 10.1111\/j.1440-1819.2007.01725.x.","journal-title":"Psychiatry Clin Neurosci"},{"key":"1596_CR19","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1080\/10543406.2013.834918","volume":"23","author":"T Song","year":"2013","unstructured":"Song T, Dong Q, Sankoh AJ, Molenberghs G: Evaluation of overall treatment in MMRM. J Biopharm Stat. 2013, 23: 1281-1293. 10.1080\/10543406.2013.834918.","journal-title":"J Biopharm Stat"}],"container-title":["BMC Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-244X-14-103.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1471-244X-14-103\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-244X-14-103","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2016,7,10]],"date-time":"2016-07-10T11:33:42Z","timestamp":1468150422000},"score":1,"resource":{"primary":{"URL":"http:\/\/bmcpsychiatry.biomedcentral.com\/articles\/10.1186\/1471-244X-14-103"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,4,7]]},"references-count":19,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,12]]}},"alternative-id":["1596"],"URL":"https:\/\/doi.org\/10.1186\/1471-244x-14-103","relation":{},"ISSN":["1471-244X"],"issn-type":[{"value":"1471-244X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,4,7]]},"article-number":"103"}}